DDInter1233 DDInter1094
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fentanyl
Fentanyl {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Mitotane {u} (Compound) resembles {v} (Compound) Delorazepam
Delorazepam {u} (Compound) resembles {v} (Compound) Flurazepam
Flurazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sufentanil
Sufentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mitotane {u} (Compound) resembles {v} (Compound) Butoconazole
Butoconazole {u} (Compound) resembles {v} (Compound) Miconazole
Miconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Carbinoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxazepam
Oxazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Eslicarbazepine {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lorlatinib
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
CYP11B1 {u} (Gene) is bound by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is upregulated by {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
CYP11B1 {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl may lead to a major life threatening interaction when taken with Lorlatinib
Mitotane (Compound) resembles Delorazepam (Compound) and Delorazepam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mitotane (Compound) resembles Butoconazole (Compound) and Butoconazole (Compound) resembles Miconazole (Compound) and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mitotane (Compound) resembles Carbinoxamine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Oxazepam and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine and Eslicarbazepine may lead to a major life threatening interaction when taken with Lorlatinib
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Mitotane (Compound) binds CYP11B1 (Gene) and CYP11B1 (Gene) is bound by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mitotane (Compound) upregulates ADGRE5 (Gene) and ADGRE5 (Gene) is upregulated by Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mitotane (Compound) binds CYP11B1 (Gene) and CYP11B1 (Gene) is bound by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Lorlatinib